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Background: Biosynthetic trafficking of receptors and other membrane-associated proteins from the endoplasmic
reticulum (ER) to the plasma membrane (PM) underlies the capacity of these proteins to participate in crucial cellular
roles. Phosphoinositides have been shown to mediate distinct biological functions in cells, and phosphatidylinositol
4-phosphate (PI4P), in particular, has emerged as a key regulator of biosynthetic trafficking.
Results: To investigate the source of PI4P that orchestrates trafficking events, we developed a novel flow cytometry
based method to monitor biosynthetic trafficking of transiently transfected proteins. We demonstrated that our
method can be used to assess the trafficking of both type-1 transmembrane and GPI-linked proteins, and that it can
accurately monitor the pharmacological disruption of biosynthetic trafficking with brefeldin A, a well-documented
inhibitor of early biosynthetic trafficking. Furthermore, utilizing our newly developed method, we applied
pharmacological inhibition of different isoforms of PI 4-kinase to reveal a role for a distinct pool of PI4P,
synthesized by PI4KIIIα, in ER-to-PM trafficking.
Conclusions: Taken together, these findings provide evidence that a specific pool of PI4P plays a role in biosynthetic
trafficking of two different classes of proteins from the ER to the Golgi complex. Furthermore, our simple, flow
cytometry-based biosynthetic trafficking assay can be widely applied to the study of multiple classes of proteins
and varied pharmacological and genetic perturbations.
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Studies of the phosphorylated derivatives of phos-
phatidylinositol (PI) have shown that these molecules
possess distinct biological functions and localize select-
ively to organelles (reviewed by [1]). Due to variable
phosphorylation of hydroxyl groups on their inositol
rings, seven different inter-convertible phosphoinositide spe-
cies exist in cells, including PI4P and phosphatidylinositol
4,5-bisphosphate (PI(4,5)P2). Different phosphoinositide* Correspondence: bryantkl@email.unc.edu
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unless otherwise stated.species are often enriched in distinct intracellular
membranes; for example, PI(4,5)P2 is predominately
localized to the inner leaflet of the PM, whereas PI4P is
enriched at the Golgi complex.
PI(4,5)P2 is a well-established regulator of multiple
cellular processes, including vesicle trafficking [2],
phagocytosis [3], membrane ruffling [4], cell motility
and adhesion [5], and regulation of ion channel activity
and receptor phosphorylation [6,7]. In addition, PI(4,5)P2
is the substrate for generation of the second messengers
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)
[8], and thereby is necessary for agonist-stimulated
Ca2+ signaling. Furthermore, there have been several reportsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pools in the PM that support specific signaling platforms
[9-12]. PI4P, the most prevalent mono-phosphorylated
PI-derivative in cells [13], was for many years believed to
serve no function outside of being the precursor for PIP2
[14]. Recently, however, a number of PI4P-dependent
processes have been characterized, in particular its
role in the regulation of protein trafficking. For example,
PI4P strongly promotes COPII-mediated export of proteins
at endoplasmic reticulum (ER) exit sites (ERES; [15,16]).
Also, by interacting with the lipid transfer proteins CERT,
OSBP, and FAPP (collectively termed COFs), PI4P plays
roles in sphingolipid and sterol biosynthetic trafficking [17].
Organelle-specific phosphoinositide distributions are
maintained by the tight regulation of PI-kinases and
PI-phosphatases. Four distinct PI 4-kinases have been
described in mammalian cells, including type II (PI4KIIα
and PI4KIIβ) and type III (PI4KIIIα and PI4KIIIβ) kinases
[18]. The type II PI 4-kinases are palmitoylated [19] and
thus strongly membrane associated, particularly in the
trans-Golgi apparatus [20], and, to a lesser extent, in
endosomes [21]. PI4KIIIβ localizes primarily to the Golgi
apparatus, coincident with Arf1, a small GTP-binding
protein [22,23]. Although the molecular details of how
these enzymes are linked to Golgi-derived biosynthetic
transport remain unknown, they have all been implicated
in Golgi function and secretion [21]. Deletion of the gene
for PI4KIIIα is embryonically lethal in mice [24], and its
normal subcellular distribution is complex, with evidence
for cytosolic [24], PM [24,25], and ER [22] concentration.
Recently, PI4KIIIα has been identified as a critical host
factor for hepatitis C viral replication [26]. With regard
to biosynthetic trafficking, PI4P localized to the Golgi
apparatus has been implicated in the delivery of cargo
from the Golgi to the PM [27,28], in addition to evidence
supporting a role for PI4P in COPII nucleation at ERES
cited above [15,16].
The present study addresses PI4P participation in
ER-to-Golgi trafficking. Using a novel technique to
monitor protein biosynthetic trafficking, we show
that pharmacological inhibition of PI4KIIIα results in
ER-retention of both the epidermal growth factor receptor
(EGFR) and a glycophosphatidylinositol (GPI)-anchored
protein. Furthermore, we show that inhibition of a
Golgi-localized PI 4-kinase does not result in ER-retention.
Taken together, these findings provide evidence that a spe-
cific pool of PI4P, synthesized by PI4KIIIα, is essential for
biosynthetic protein trafficking.
Results
Flow cytometry of transiently transfected cells to assess
perturbations of early ER-to-Golgi trafficking events
Preliminary experiments indicated that testing the effects
of potential inhibitors of ER-to-Golgi trafficking requires amethod in which a substantial percentage of trans-
fected protein makes this transition simultaneously.
To synchronize the early stages of biosynthetic trafficking,
we developed a protocol in which RBL-2H3 mast cells are
incubated at 22°C for 14 hr following transient transfection
with EGFR-GFP. This incubation at lower temperature
allows for protein synthesis to occur with minimal
trafficking to the PM [29,30]. The next day, the cells
are transferred to 37°C, at which time biosynthetic
trafficking begins. Cells are harvested and fixed at the
various time points (depending on the experiment), and
unpermeabilized cells are labeled with an antibody specific
for an extracellular epitope. Thus, the increased presence
of EGFR-GFP at the PM can be quantified over time by
flow cytometry by measuring the total EGFR-GFP fluores-
cence and comparing it to the fluorescence of the extracel-
lular epitope-labeling antibody. Representative confocal
images of the suspended flow cytometry samples show that
6 hr after transfer to 37°C, EGFR is clearly detectable at the
PM (Figure 1A). In agreement with previous reports on
the timescale of EGFR protein maturation [31], most cells
show predominantly ER-localized EGFR at 2 hr after
transfer, with no detectable labeling at the PM, and
by 4 hr significant Golgi localization is observed, with
some receptor localization at the PM (Figure 1A).
Under these conditions, trafficking of EGFR-GFP to the
PM is maximal by 10 hr at 37°C, as quantified by flow
cytometry (Figure 1B,C).
To determine whether we could accurately monitor the
pharmacological disruption of biosynthetic trafficking
using this method, we first tested the effects of brefeldin
A (BFA), a well-documented inhibitor of early biosynthetic
trafficking [32]. Because we observed that EGFR transfers
from ER to Golgi by 4 hr after the temperature shift
(Figure 1A), we chose to apply the inhibitor at 3 hr.
When RBL cells expressing EGFR-GFP are treated
with 5 μg/ml BFA under these conditions, EGFR-GFP
trafficking to the PM is prevented (Figure 2A), and
EGFR-GFP exhibits an intracellular distribution (Figure 2B).
Evidence that EGFR-GFP is retained in the ER in the
presence of BFA is provided by immunofluorescence
co-localization with the resident lumenal ER protein,
PDI (Figure 3A).
Inhibition of PI4KIIIα by PAO prevents EGFR trafficking
from the ER to the Golgi apparatus
Based on previous evidence for a role for PI4P in COPII
nucleation at ERES [15,16], we hypothesized that a pool
of PI4P generated by PI4KIIIα is necessary for proper
biosynthetic trafficking from the ER to the Golgi apparatus.
Phenylarsine oxide (PAO) is an inhibitor of PI 4-kinases
[33], which, when present in low micromolar concentra-
tions, selectively inhibits the PI4KIIIα isoform [18,21]. We
recently showed that PAO inhibits IgE receptor signaling
Figure 1 Robust trafficking of EGFR to the PM upon transferring expressing cells to 37°C following 14 hrs at 22°C. Live cells transiently
expressing EGFR-GFP were harvested for flow cytometry, then fixed at each time point. Cells were incubated with an anti-N-terminal EGFR
antibody followed by Alexa647-anti-IgG to label PM-associated EGFR, then imaged by confocal microscopy (A) or analyzed by flow cytometry
(B) to determine the ratio of PM-localized EGFR fluorescence to total-EGFR fluorescence. Plot is representative of typical results; approximately
8,000 EGFR-GFP expressing cells were analyzed at each time point, and the ratios for all time points were normalized to that at 8 hr. Scale bars
in A are 5 μm. (C) Representative flow cytometric scatter plots. RBL-2H3 cells transiently expressing GFP-tagged EGFR constructs were harvested,
fixed, and labeled with anti-N-terminal EGFR antibody followed by Alexa 647-anti-IgG. Cells were gated on positive GFP fluorescence (blue and
purple populations), and Alexa 647 fluorescence was analyzed to determine PM localization (purple population). Bold numbers indicate the mean
Alexa 647 fluorescence of the GFP-positive population. Plots are representative of data used to generate “control” traces in Figures 1, 2, 4, and 7.
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phosphorylation in RBL mast cells by a mechanism
consistent with inhibition of phosphoinositide synthesis
[34]. Under these conditions, acute addition of PAO does
not inhibit IgE receptor-mediated tyrosine phosphoryl-
ation or thapsigargin-stimulated Ca2+ mobilization. When
RBL cells expressing EGFR-GFP are treated with 2.5 μM
PAO, trafficking of these receptors to the PM is prevented(Figure 4A), and concentrations as low as 1.5 μM substan-
tially inhibit biosynthetic trafficking (Figure 4B). In the
presence of 2.5 μM PAO, EGFR-GFP is retained
intracellularly (Figure 4C) and is co-localized with
PDI throughout the ER (Figure 3A). When biosynthetic
trafficking out of the ER is assessed by susceptibility to
digestion by endoglycosidase H (EndoH), we find that
2.5 μM PAO substantially inhibits the appearance of an
Figure 2 Treatment with brefeldin A inhibits the biosynthetic
trafficking of EGFR to the PM. Live cells transiently expressing
EGFR-GFP were processed as described for Figure 1, except that BFA
(5 μg/ml) was added to half of the cells at hour 3. (A) Flow cytometry
was used to calculate the ratio of PM localized EGFR fluorescence to
total EGFR fluorescence, and this ratio for each time point ± BFA is
plotted. Error bars indicate ± SE of four independent experiments in
which approximately 8,000 EGFR-GFP expressing cells were analyzed
at each time point. *** p < 0.001 (B) Confocal images of RBL cells
expressing EGFR-GFP either untreated or treated with BFA, cells are
from 8 hr time points quantified in A. Scale bars show 5 μm.
Figure 3 EGFR-GFP is ER-retained in cells treated with BFA
(5 μg/ml) and PAO (2.5 μM), whereas in wortmannin (10 μM)
treated cells, retention occurs in the ER and Golgi apparatus.
(A) Attached RBL cells transiently expressing EGFR-GFP were processed
as described for Figure 1, except that inhibitors were added at hour 3.
At hour 8 cells were fixed, permeabilized, and incubated with an
anti-PDI antibody followed by Alexa 555-anti-mouse IgG to label the
ER lumen. (B) The same cells shown in A were incubated with an
anti-GM130 antibody followed by Alexa 647-anti-mouse IgG to label
the Golgi apparatus. Scale bars show 5 μm.
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cleaving N-linked oligosaccharide chains near their site
of attachment to the protein, and, once a protein has
trafficked to the Golgi, further oligosaccharide processing
results in resistance to EndoH digestion. Peptide-N-
Glycosidase F (PNGase F) removes all glycosylations, and
serves as a control for these assays. The appearance of an
EndoH-resistant pool of EGFR in the 3 hr control sample
in Figure 5 indicates that some exit from the ER has
occurred by this time point, even though this is minimally
detectable after 2 hr by flow cytometry and confocal
microscopy (Figure 1).The requirement of PI4P synthesized by PI4KIIIα for
ER-to-Golgi trafficking is not limited to EGFR or type-1
transmembrane proteins
The GPI anchor is a posttranslational modification that
results in expression of modified proteins in the outer
leaflet of the PM [35]. Synthesis of the GPI-linker begins
on the cytoplasmic face of the ER; the precursor is then
flipped to the lumenal side of the ER for further process-
ing and protein attachment before trafficking to the PM
[36]. We performed our biosynthetic trafficking protocol
Figure 4 Treatment with PAO inhibits the biosynthetic
trafficking of EGFR to the PM in a dose-dependent manner. Live
cells transiently expressing EGFR-GFP were processed as described
for Figure 1, except that PAO was added at indicated concentrations
to half of the cells at hour 3. (A) Flow cytometry was used to
calculate the ratio of PM localized EGFR fluorescence to total EGFR
fluorescence, and this ratio for each time point ± PAO (2.5 μM) is
plotted. Error bars indicate ± SE of five independent experiments in
which approximately 8,000 EGFR-GFP expressing cells were analyzed
at each time point. *** p < 0.001 (B) Dose-dependence of PAO
inhibition of biosynthetic trafficking of EGFR. Samples were processed
as in A following addition of indicated concentrations of PAO. Data
from one experiment is representative of 2 separate experiments;
approximately 8,000 EGFR-GFP expressing cells were analyzed at each
time point. (C) Confocal images of RBL cells expressing EGFR-GFP
either untreated or treated with PAO, cells are from 8 hr time points
quantified in A. Scale bar shows 5 μm.
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a heavily glycosylated surface protein of broad tissue dis-
tribution [37], fused to YFP. In the hours following the
temperature shift, we observed increased PM expression
of GPI-YFP, and this process was prevented by treating
the cells with 2.5 μM PAO (Figure 6). These results
suggest that PI4P synthesized by PI4KIIIα is involved
in ER-to-PM trafficking of at least two different classes of
proteins.
Treatment with the PI4K inhibitors wortmannin and
quercetin prevent the biosynthetic trafficking of EGFR to
the PM
Although low micromolar concentrations of PAO select-
ively inhibit the type-IIIα isoform of PI 4-kinase, PAO can
also inhibit tyrosine phosphatases at these concentrations
[38]. To distinguish whether retention of EGFR in the ER
upon PAO treatment is due to phosphatase or PI 4-kinase
inhibition, we tested the effects of the PI 4-kinase inhibitors
wortmannin and quercetin [2-(3,4-dihydroxy-phenyl)-3,5,7-
trihydroxy-4H-chromen-4-one], neither of which inhibits
tyrosine phosphatases at the concentrations used [34,39,40].
Nanomolar concentrations of wortmannin have been
shown to inhibit PI3-kinase (IC50 = 5 nM) [41], whereas
significantly higher concentrations are needed to similarly
inhibit PI 4-kinases [42,43]. We found that 10 μM
wortmannin prevents EGFR-GFP from trafficking to the
PM (Figure 7A), and this receptor is intracellularly
retained (Figure 7B), with some localization in both the
ER and the Golgi apparatus (Figure 3A,B). When cells are
treated with 200 nM wortmannin, EGFR-GFP biosynthetic
trafficking to the PM is somewhat diminished (Figure 7A);
but still readily detectable there (Figure 7B), indicating
that inhibition of PI3-kinase is not sufficient to prevent
EGFR-GFP trafficking to the PM. Quercetin has been
shown to generally inhibit kinases, including PI kinases, by
competition with ATP for the active site [44]. Quercetin
significantly reduces biosynthetic trafficking of EGFR
Figure 6 Treatment with PAO inhibits the biosynthetic
trafficking of GPI to the PM. Live cells transiently expressing
GPI-YFP were processed as described for EGFR expressing cells, PAO
(2.5 μM) was added to half of the cells at hour 3. (A) Flow cytometry
was used to calculate the ratio of PM localized GPI fluorescence,
detected by anti-GFP, to total GPI fluorescence, and this ratio for each
time point ± PAO (2.5 μM) is plotted. Error bars indicate ± SD of three
independent experiments in which approximately 8,000 GPI-YFP
expressing cells were analyzed at each time point, and all time points
were normalized to the control ratio at 7 hr, ** p < 0.01. (B) Confocal
images of attached RBL cells expressing GPI-YFP either untreated or
treated with PAO for 6 hr, as quantified in A. Scale bar shows 5 μm.
Figure 5 Analysis of biosynthetic trafficking by susceptibility to
digestion by endoglycosidase H. RBL mast cells transiently expressing
pkH3-EGFR were subjected to the same trafficking protocol as described
in Figure 1. However, rather than processing samples for flow cytometry,
whole cell lysates were collected and were either untreated (Un), treated
with EndoH (EH), or treated with PNGase F (PNG) for 24 hr before
Western blot analysis with an anti-EGFR antibody. The EGFR protein
from the PAO treated cells is completely Endo H sensitive by 7 hr, thus
supporting the contention that these EGFR proteins contain only
N-linked oligosaccharide chains and have not trafficked beyond the ER.
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detected at the PM after 8 hr when cells are treated with
20 μM quercetin (Figure 7C,D). As with wortmannin,
inhibition by quercetin results in substantial accumulation
of EGFR in the Golgi apparatus, suggesting that these PI
kinase inhibitors are less effective at inhibiting ER to
Golgi trafficking than PAO. None-the-less, inhibition
of biosynthetic trafficking by wortmannin and quercetin
(Figure 7) is consistent with the conclusion that inhibition
of trafficking with PAO (Figure 4) is primarily due to the
inhibition of a PI kinase, rather than inhibition of tyrosine
phosphatases.
Organelle-specific PI-kinases and phosphatases dictate
distinct subcellular distributions of the individual PI
species that control the timing and location of trafficking
events [23]. Based on immunofluorescence, PI4KIIIα has
been suggested to localize to the ER [22], but a more
recent study indicates a largely cytoplasmic distribution
[24]. Both of the type-II PI 4-kinases localize to theGolgi complex and endosomes, and PI4KIIIβ localizes
more selectively to the Golgi complex [18]. To determine
whether inhibition of a different isoform of PI4K similarly
inhibits biosynthetic trafficking of EGFR from the ER to
the Golgi apparatus, we tested the possible role of
cis-Golgi localized PI4KIIIβ. PIK-93 (phenylthiazole) is
a selective inhibitor of PI4KIIIβ (IC50 = 19 nM; [45]),
and we found that this compound does not significantly
affect the biosynthetic trafficking of EGFR-GFP, even when
used at a concentration (1 μM) that should completely
inhibit PI4KIIIβ (Figure 8A,B). To confirm its potency, we
tested the effect of PIK-93 on degranulation of RBL cells in
Figure 7 Treatment with the PI4K inhibitors wortmannin and quercetin prevents the biosynthetic trafficking of EGFR to the PM. Live
cells transiently expressing EGFR-GFP were processed as described for Figure 1, except that wortmannin (200 nM or 10 μM) or quercetin (20 μM)
were added at hour 3. (A) Flow cytometry was used to calculate the ratio of PM localized EGFR fluorescence to total EGFR fluorescence, and this
ratio for each time point ± wortmannin is plotted. Error bars indicate ± SE of five independent experiments in which approximately 8,000 EGFR-GFP
expressing cells were analyzed at each time point. * p < 0.05; *** p < 0.001 (B) Representative confocal images of RBL cells expressing EGFR-GFP either
untreated or treated with 200 nM or 10 μM wortmannin from 8 hr time points quantified in A. (C) Flow cytometry was used to calculate the ratio of
PM localized EGFR fluorescence to total EGFR fluorescence, and this ratio for each time point ± quercetin is plotted. Error bars indicate ± SE of four
independent experiments in which approximately 8,000 EGFR-GFP expressing cells were analyzed at each time point. ** p < 0.01 (D) Representative
confocal images of RBL cells expressing EGFR-GFP either untreated or treated with 20 μM quercetin from 8 hr time points quantified in C. Two different
cells with 20 μM quercetin shown to represent the range of distributions observed. Scale bars show 5 μm.
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utilize PI4KIIIβ [46]. As shown in Figure 8C, we find that
1 μM PIK-93 reduces stimulated degranulation by approxi-
mately 35%, consistent with reduction in degranulation
observed with PI4KIIIβ silencing [46].
Discussion
Previous biosynthetic trafficking studies have frequently
relied on the use of the temperature sensitive mutant of
vesicular stomatitis virus glycoprotein (VSV-Gts), which
can be synchronized to undergo ER to PM trafficking in
a temperature-dependent manner [47]. The method we
describe can be utilized to evaluate biosynthetic trafficking
of a wide variety of transiently transfected proteins in
different cell types without the necessity of pulse-chase
radiolabeling and immunoprecipitation. Following transienttransfection, cells are incubated overnight at a restrictive
temperature (room temperature, 22°C, in the present
study). During this incubation, protein synthesis occurs
without subsequent protein trafficking out of the ER.
The following day, when cells are shifted to 37°C, the
synthesized protein moves through the biosynthetic
pathway and its presence at the PM can be monitored
over time (Figure 1).
Although incubation at 22°C has been reported to
impair biosynthetic trafficking from the ER in some
cell systems [29,30]; this temperature may not be univer-
sally applicable, as 15°C is more generally considered
necessary to block biosynthetic trafficking at the level
of the ER-exit sites and/or ERGIC [48,49]. This lower
temperature may be an alternative in other applications.
Additionally, EGFR is a PM localized protein that has a
Figure 8 Treatment with PIK-93 does not significantly affect
the biosynthetic trafficking of EGFR to the PM. Live cells
transiently expressing EGFR-GFP were processed as described for
Figure 1, except that 1 μM PIK-93 was added to half of the cells at
hour 3. (A) Flow cytometry was used to calculate the ratio of PM
localized EGFR fluorescence to total EGFR fluorescence, and this ratio
for each time point ± PIK-93 is plotted. Error bars indicate ± SE of five
independent experiments in which approximately 8,000 EGFR-GFP
expressing cells were analyzed at each time point. n.s., not significant
(B) Representative confocal images of RBL cells expressing EGFR-GFP
either untreated or treated with 1 μM PIK-93, cells are from 8 hr time
points quantified in A. Scale bar shows 5 μm. (C) Degranulation was
measured for cells pretreated with denoted concentrations of PIK-93
for 40 min before stimulation with antigen (10 μg/ml) for 25 min. Bars
represent average degranulation response from two experiments, in
which each condition was assayed in triplicate, error bars indicate ± SD.
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the cell type and level of expression. As shown in Figure 1,
the presence of EGFR at the PM steadily increased from
hours 2 through 10 and only after hour 10 does the
ratio of PM localized EGFR fluorescence to total
EGFR fluorescence begin to decrease. Thus, in the case of
EGFR, endocytosis was not a contributing factor on the
time scale used for the pharmacological experiments;
however, this will not be the case for all potential proteins
of interest. Therefore, prior to performing pharmacological
or genetic manipulations one must determine the kinetics
of the arrival of their protein of interest at the PM as well
as the amount of time it is stably localized there, before
endocytosis becomes a contributing factor.
Our flow cytometry-based method can be used to
investigate a variety of means for intervention of biosyn-
thetic trafficking, including molecular genetic manipula-
tions. In the present study, we evaluated pharmacological
effects. We first verified that this system is sensitive to of
BFA, which is a well-documented inhibitor of this process
(Figure 2). Following this validation of our method, we
examined the trafficking of EGFR (Figures 1, 2, 3, 4, 5, 7, 8)
and a model GPI-linked protein (Figure 6), both of which
were fluorescently tagged and could be labeled with an
extracellular epitope-binding antibody to visualize the
PM-associated pool of protein. We used flow cytometry,
complemented with confocal microscopy, to analyze the
biosynthetic trafficking process. Flow cytometry is a con-
venient way to analyze thousands of positively transfected
cells in a short amount of time and thus allows for a more
rigorous statistical analysis of the data as compared to
single cell imaging. Confocal microscopy provides repre-
sentative images of our flow cytometry samples. The less
flattened morphology of these suspended RBL cells per-
mits clearer distinction of the PM than for more flattened
cells; however, this morphology is more limited in terms
of defining precise intracellular protein localizations.
Regardless of the cell system, we note that, in the event
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be differentially labeled, biochemical methods, such as
endoglycosidase H digestion assays [50], can also be
used to quantify biosynthetic trafficking following this
general approach, as demonstrated in the present
study (Figure 5).
Of the different isoforms of PI 4-kinase, PI4KIIIα is
preferentially inhibited by low micromolar concentrations
of PAO [18,21]. We find that cells treated with PAO show
a dose-dependent inhibition of biosynthetic trafficking of
EGFR-GFP to the PM (Figure 4A,B). Nearly complete
inhibition of trafficking is attained for cells treated
with 2.5 μM PAO (Figure 4), and EGFR is retained in
the ER (Figure 3). At this concentration, PAO causes
strong inhibition of downstream IgE receptor signaling that
correlates with inhibition of phosphoinositide synthesis in
these RBL cells [34].
To test the possibility that inhibition of biosynthetic
trafficking by PAO is due to the inhibition of enzymes
other than PI4KIIIα, including tyrosine phosphatases
[38], we analyzed the effects of two other PI 4-kinase
inhibitors, wortmannin and quercetin [34], which do
not inhibit tyrosine phosphatases. We observed dose-
dependent inhibition of biosynthetic trafficking of
EGFR-GFP with each (Figure 7), thus supporting the
evidence that PAO treatment inhibits biosynthetic
trafficking by inhibiting a PI 4-kinase, rather than a
tyrosine phosphatase. Never the less, we cannot completely
rule out other targets of PAO for its inhibitory effects, and
future studies will require complementary tests of this
mechanism using molecular genetic approaches.
Due to the predominant localization of the other three
PI 4-kinase isoforms (IIα, IIβ, and IIIβ) to the Golgi, we
hypothesize that a distinct pool of PI4P in the ER
synthesized by PI4KIIIα is important for biosynthetic
trafficking. This hypothesis is supported by our observa-
tion that inhibition of the Golgi-localized PI 4-kinase,
PI4KIIIβ, does not significantly affect trafficking of EGFR
to the PM (Figure 8). Although there is evidence that
Golgi to PM trafficking also requires PI4P synthesized in
the Golgi apparatus [23], we suggest that inhibition of one
of the three Golgi-localized PI 4-kinases can be compen-
sated by the other (Type II) PI4-kinases associated with
this organelle.
What is the mechanism by which PI4P participates in
the ER exit of PM-destined proteins? PI4P has been shown
to support the reconstitution of yeast COPII-dependent
budding from synthetic liposomes [15]. Consistent with
this, PI4P has been shown to promote ER exit of VSV-Gts
by regulating ERES membrane budding and COPII coat
nucleation in mammalian cells [16]. Appearance of PI4P at
ERES is transient and coincident with cargo concentration
in these sites [16]. We hypothesize that PI4P mediates its
effects on the biosynthetic trafficking of proteins viaelectrostatic interactions with basic residues in protein
sequences, located either in the cargo or in components
of the trafficking machinery. For example, the crystal
structure of Sec23-Sec24 dimer in the COPII coatmer
complex exhibits a surface of basic residues on the
membrane-facing side that may bind to PI4P [51].
Because we observe a primary accumulation of EGFR-
GFP and GPI-YFP in the ER of RBL cells in which PI4KIIIα
has been inhibited by PAO, it is likely that this accumu-
lation is due to depletion of an ER-localized pool of PI4P
necessary for exiting the ER. Alternatively, accumulation
in the ER could result from depletion of a Golgi-localized
pool of PI4P that results in retrograde trafficking to the
ER. The localization of PI4KIIIα is complex: Mammalian
PI4KIIIα is the homolog of yeast Stt4, a PM-associated
protein [52] that has more recently been suggested to
localize to specific regions of the PM called PI-kinase
(PIK) patches, important for signaling [53]. Paradoxically,
although Stt4 is not commonly detected in the ER in
yeast, the PI4P pool generated by this kinase is mainly
dephosphorylated by the ER-localized phosphoinositide
phosphatase, Sac1p [54]. Additionally, PI4KIIIα contains a
FFAT (two phenylalanines [FF] in an acidic track) motif
that binds to the integral ER proteins Scs2/22 in
yeast, or VAP proteins in mammals [55], consistent
with localization to the ER. In mammalian cells,
PI4KIIIα was initially reported to localize primarily to
the ER based on immunofluorescence [22]. Furthermore,
it has been demonstrated that silencing of PI4KIIIα by
siRNA results in a large reduction in the number of ERES,
which in turn correlates with decreased ER-to-Golgi
transport [56]. However, PI4KIIIα also has been reported
to be responsible for the generation of hormone-sensitive
phosphoinositide pools in the PM [25], and a recent re-
port describes a predominantly cytoplasmic localized
PI4KIIIα distribution with some PM association that
contributes to PM identity [24].
Future work to visualize and selectively deplete PI4P
either in the ER or the Golgi apparatus may lead to better
understanding of the roles of the pools of PI4P in each of
these organelles that are important for biosynthetic
trafficking. The Sac1 phosphatase cycles between the ER
and Golgi apparatus and is a key regulator of PI4P in
mammalian cells [57]. Szentpetery et al. [27] recently
described a drug-inducible molecular approach to
specifically target the effects of Sac1 phosphatase activity
to a particular intracellular membrane. Use of this tech-
nique to selectively deplete PI4P either in the ER or the
Golgi apparatus may lead to better understanding of the
origins of the pools of PI4P important for biosynthetic
trafficking. While the localization of PI4P to the Golgi has
been extensively reported, new tools to visualize PI4P
pools in cells have revealed pools of this lipid associated
with the PM and late endosomes/lysosomes [58]. It will be
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are capable of recognizing an ER-associated pool of PI4P
in this cell system. Alternatively, further support for the
necessity of PI4KIIIα activity, as implicated by our
pharmacological approach, could be provided with the
use of siRNA to genetically silence this protein. The
flow cytometry based method we have developed will con-
tinue to be useful in evaluating these more molecular
approaches.Conclusions
Biosynthetic trafficking of receptors and other membrane
proteins to the PM underlies the capacity of these proteins
to participate in crucial cellular functions. Elucidating the
mechanisms of the trafficking process is fundamental to
understanding and interfering with the cellular responses
that PM-localized receptors regulate. Toward this end, we
developed a novel flow cytometry-based method to exam-
ine the biosynthetic trafficking of transiently transfected
proteins. We utilized this method to show that PI4P is
important for biosynthetic trafficking of both a trans-
membrane and a GPI-linked protein to the PM. In
particular, we took advantage of a number of well-
characterized inhibitors of the different PI 4-kinase
isoforms [18] to provide pharmacological evidence
that the type IIIα isoform of PI4K may be responsible
for synthesizing the relevant pool of PI4P. This simple,
flow-cytometry based biosynthetic trafficking method
could be widely applicable to different classes of proteins
and inhibitors using pharmacological and molecular
approaches.Methods
Materials and expression plasmids
All cell culture reagents and all Alexa-dye conjugated
secondary antibodies were from Invitrogen. The anti-N-
terminal human EGFR antibody (clone LA1) used for flow
cytometry and immunochemistry, and the anti-C-terminal
human EGFR antibody (clone E235) used for immuno-
chemistry were from Millipore Corp. Anti-protein disulfide
isomerase (PDI) mAb was from Affinity Bioreagents, and
anti-GM130 was from BD Biosciences. PIK-93 was
from Symansis; wortmannin and brefeldin-A were
from Calbiochem. Anti-GFP mAb, phenylarsine oxide
(PAO), quercetin, as well as any chemical not noted
otherwise were purchased from Sigma-Aldrich Chemical
Co. The human EGFR-GFP construct was a gift from
Dr. J. Koland (U. Iowa) and has been described previously
[59]. YFP-GPI, a gift from Dr. T. Baumgart (U. Penn.) is a
GPI-anchored protein containing yellow fluorescent
protein and a consensus N-glycosylation site fused to the
GPI-attachment signal of lymphocyte-function-associated
antigen 3 (LFA-3) [60].Cell culture
RBL-2H3 mast cells were grown in MEM containing 20%
(v/v) fetal bovine serum (FBS) (Atlanta Biologicals) and
10 μg/ml gentamicin sulfate as described previously [61].
In preparation for imaging or flow cytometry, cells were
plated at 25-50% confluence in 35 mm coverslip wells
(MatTek Corporation) or 60 mm dishes, respectively.
After approximately 20 h, the RBL cells were transfected
with EGFR-GFP or YFP-GPI using Fugene HD (Promega)
per manufacturers’ instructions, with modification to
enhance transfection efficiency in the RBL cells previously
described [61].
Biosynthetic trafficking method
On day one, approximately 1x106 RBL cells were plated
in 60 mm dishes or 3.5x105 RBL cells were plated in
35 mm coverslip dishes. On day two, cells were trans-
fected using Fugene HD as described above. Cells were
allowed to recover from transfection for 30 min to 1 hr
at 37°C in culture medium. Subsequently, the medium
was buffered with 40 mM HEPES, and the dishes were
sealed with parafilm and incubated at room temperature
in the dark for 12 to 14 hr. On day three, cells were
returned to regular culture medium and placed at 37°C;
this point is time zero in the time course. For most
experiments, pharmacological agents were diluted in
buffered saline solution (BSS: 20 mM HEPES,
135 mM NaCl, 1.8 mM CaCl2, 2 mM MgCl2, 5.6 mM
glucose, 1 mg/ml BSA, pH 7.4) and added at hour 3
of the time course (for control samples, culture
medium was replaced with BSS at this time in parallel).
Samples from each time point were processed for
confocal fluorescence microscopy or flow cytometry
as described below.
Confocal fluorescence microscopy
RBL cells were washed once with BSS, fixed using 4%
paraformaldehyde with 0.1% glutaraldehyde, perme-
abilized (or not) with 1% v/v Triton X-100, and labeled for
1 hour with specified antibodies in phosphate buffered
saline (PBS) with 10 mg/ml BSA and 0.01% w/v sodium
azide (PBS/BSA). Images were collected using an upright
Leica TCS SP2 laser scanning confocal microscope (Leica
Microsystems, Exton, PA) with a 63 x 0.9 NA, HCX APO
L U-V-I water-immersion objective.
Flow cytometry
Herein, RBL cells were harvested by trypsinization; however,
commercial non-enzymatic dissociation reagents or PBS/
EDTA could be similarly used if there is concern trypsin
could harm the protein of interest. Following dissociation,
cells were washed once with BSS, fixed using 4% parafor-
maldehyde with 0.1% glutaraldehyde, and quenched with
PBS/BSA. Cells expressing EGFR-EGFP or YFP-GPI
Bryant et al. BMC Cell Biology  (2015) 16:5 Page 11 of 12constructs were labeled with appropriate antibodies
for 1 hr in PBS/BSA. Samples were evaluated using a
Becton Dickinson (BD) LSR II flow cytometer, and
data were analyzed using BD FACSDiva software.
Analysis was gated to include single cells on the basis
of forward and side light-scatter, and data from
single-color samples were used to determine the gates
for positive fluorescence from each fluorophore. The
ratio of PM-associated EGFR fluorescence (Alexa 647
antibody labeled) to total EGFR-GFP fluorescence was
normalized to the 7 or 8 hr time point for each time-
course shown.
EndoH sensitivity assay
To generate whole cell lysates, RBL cells were washed in
PBS, incubated in lysis buffer (25 mM Tris, pH 7.4,
100 mM NaCl, 1 mM EDTA, 1% (v/v) Triton 100, 1 mM
DTT, 1 mM sodium orthovanadate, 1 mM β-glycerol
phosphate, 1 μg/ml leupeptin, and 1 μg/ml aprotinin), and
supernatants were retained following microcentrifuge
centrifugation. Protein concentrations of the whole
cell lysates were determined using the Bio-Rad DC
protein assay. Whole-cell lysates were divided into
three equal portions that then were untreated, or
treated with EndoH or PNGase F according to the
manufacturer’s instructions (New England Biolabs).
Samples were incubated for 24 h at 37°C, and the diges-
tion reactions were stopped by heating at 95°C for 5 min
after the addition of SDS-PAGE sample buffer. Samples
were analyzed by immunoblotting.
Degranulation: β-Hexosaminidase Release
Cells were plated in triplicate at a density of 5x105/well
and incubated overnight in the presence of 1 μg/ml
anti-DNP IgE. The next day, cells were treated with
PIK-93 (250 nM or 1 μM) for 40 min in BSS without
BSA, and β-hexosaminidase release in response to
DNP-BSA was assessed as described previously [62].
Data analysis
Statistical analyses were determined using GraphPad
Prism (GraphPad Software, La Jolla, CA) using Student’s t
test, with p < 0.05 considered statistically significant.
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